Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,533 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amount and selectivity of proteinuria may predict the treatment response in post-transplant recurrence of focal segmental glomerulosclerosis: a single-center retrospective study.
Ban H, Miura K, Kaneko N, Shirai Y, Yabuuchi T, Ishizuka K, Chikamoto H, Akioka Y, Shimizu S, Ishida H, Tanabe K, Hattori M. Ban H, et al. Among authors: shimizu s. Pediatr Nephrol. 2021 Aug;36(8):2433-2442. doi: 10.1007/s00467-021-04951-x. Epub 2021 Feb 4. Pediatr Nephrol. 2021. PMID: 33538912
Risk factors for hyponatremia after hypotonic fluid infusion.
Shirai Y, Miura K, Shimizu S, Hattori M, Shimizu N. Shirai Y, et al. Among authors: shimizu s, shimizu n. Pediatr Int. 2019 Dec;61(12):1239-1243. doi: 10.1111/ped.14000. Epub 2019 Dec 13. Pediatr Int. 2019. PMID: 31469462
Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
Imaoka H, Sasaki K, Machida R, Nagano H, Satoi S, Ikeda M, Kobayashi S, Yamashita T, Okusaka T, Ido A, Hatano E, Miwa H, Ueno M, Nakao K, Shimizu S, Kuramochi H, Sakamori R, Tsumura H, Okano N, Shioji K, Shirakawa H, Akutsu N, Tsuji K, Ishii H, Umemoto K, Asagi A, Ueno M; JCOG Hepatobiliary and Pancreatic Oncology Group. Imaoka H, et al. Among authors: shimizu s. Jpn J Clin Oncol. 2024 Jun 7:hyae048. doi: 10.1093/jjco/hyae048. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 38843879
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW. Oh DY, et al. Among authors: shimizu s. Lancet Gastroenterol Hepatol. 2024 May 29:S2468-1253(24)00095-5. doi: 10.1016/S2468-1253(24)00095-5. Online ahead of print. Lancet Gastroenterol Hepatol. 2024. PMID: 38823398
4,533 results